Diagnostic delay in IPF impacts progression-free survival, quality of life and hospitalisation rates

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 601 KB, PDF-dokument

Background The diagnosis of idiopathic pulmonary fibrosis (IPF) is often delayed up to several years. The objective of this study was to assess the impact of the diagnostic delay on progression-free survival, quality of life and hospitalisation rates. Methods A total of 264 incident patients with IPF were included immediately after their diagnosis and followed for up to 5 years, with regular collection of clinical data, quality-of-life questionnaires and assessment of disease progression. Hospitalisation data were extracted from electronic patient records. Analyses were performed on the entire cohort and strata according to forced vital capacity (FVC) at diagnosis. Results A long diagnostic delay (>1 year) was associated with worse progression-free survival compared with a short diagnostic delay (<1 year) (HR: 1.70, 95% CI: 1.18 to 2.46, p=0.004) especially in patients with mild disease at the time of diagnosis (FVC>80% predicted). Mean total scores of the St. George's respiratory questionnaire (SGRQ), a derived IPF-specific version of the SGRQ and the chronic obstructive pulmonary disease assessment test (CAT) were consistently higher in patients with long diagnostic delays, indicating worse quality of life. Mean hospitalisation rates were higher during the first year after diagnosis (Incidence rate ratio [IRR]: 3.28, 95% CI: 1.35 to 8.55, p=0.01) and during the entire follow-up (IRR: 1.74, 95% CI: 1.01 to 3.02, p=0.04). Conclusion A diagnostic delay of more than 1 year negatively impacts progression-free survival, quality of life and hospitalisation rates in patients with IPF. These findings highlight the importance of an early diagnosis for proper management of IPF. Trial registration number NCT02755441.

OriginalsprogEngelsk
Artikelnummere001276
TidsskriftBMJ Open Respiratory Research
Vol/bind9
Udgave nummer1
ISSN2052-4439
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
This study was funded by unrestricted research grants from Aase og Ejnar Danielsens Fond (Aase and Einar Danielsens Foundation), Roche a/s and Skibsreder Per Henriksen, R. og Hustrus Fond (Shipowner Per Henriksen, R and wife Foundation). The funding sources had no influence on the study design; the collection, analysis or interpretation of the data; in the writing of the report; or in the decision to submit the paper for publication.

Funding Information:
NH reports unrestricted research grants from Aase og Ejnar Danielsens Fond, Roche and Skibsreder Per Henriksen, R. og Hustrus Fond. TSP reports an unrestricted research grant from Boehringer Ingelheim, contact with Galapagos and consulting fees from Boehringer Ingelheim. EB reports payment for presentations from Boehringer Ingelheim, Hofmann la Roche, Galapagos and Astra Zeneca, support for attending meetings from Boehringer Ingelheim and Hofmann la Roche, and participation in advisory boards for Boehringer Ingelheim and Hofmann la Roche. SBS reports payment for presentations from Boehringer Ingelheim and Roche, support for attending meetings from Boehringer Ingelheim, and participation in advisory board for Boehringer Ingelheim.

Publisher Copyright:
©

ID: 321837678